FIGURE 6.

In older Abcd1‐null mice, PXL065 lowers spinal cord very long chain fatty acids, improves sciatic nerve morphology and enhances neurobehavioral functions. Older (age 13 months) Abcd1‐null mice were treated for 12 weeks with PXL065 or pioglitazone (15 mg/kg QD). (A) C26:0 content measured in spinal cord by mass spectrometry; results are mean ± SEM, n = 8 animals/condition. (B) Open‐field test monitoring results. Data are mean ± SEM, n = 8 animals/condition (seven animals for wild‐type in graph presenting number of rearings). (C) Axonal morphology (with representative images) of neurons determined by morphometric analysis of transversal slices of the sciatic nerve by electronic microscopy (800×). Data are mean ± SEM, n = 4 animals/condition. * p < 0.05, ** p < 0.01, **** p < 0.0001 by one‐way analysis of variance followed by Dunnett's multiple comparison or by Kruskal–Wallis followed by Dunn's multiple comparison vs untreated Abcd1‐null mice